neurotrophic tyrosine receptor kinase [NTRK]
oncogenic NTRK gene fusions occur in many different tumour types. while present in a majority of certain rare tumours, such as secretory carcinoma of the breast or salivary gland and infantile fibrosarcoma, they are also rarely present in many common cancers such as melanoma, glioma and carcinomas of the thyroid, lung and colon.
with the recent approvals of NTRK targeted therapy and the marked and durable responses these agents produce in patients with NTRK fusion-positive cancers, identification of tumours harbouring these fusions has become essential. NTRK targeted therapies are among the first tumour agnostic treatments to be approved. this means that patients with advanced solid tumours harbouring an NTRK gene fusion across multiple tumour types and ages are eligible to receive this type of treatment.
in canada, larotrectinib and entrectinib have been approved for the treatment of adult and pediatric patients [larotrectinib only] with solid tumours that have an NTRK gene fusion